Alligator Bioscience AB (LTS:0RK9)
kr 1.256 0 (0%) Market Cap: 934.77 Mil Enterprise Value: 869.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 33/100

Q4 2019 Alligator Bioscience AB Earnings Call Transcript

Feb 12, 2020 / 08:00AM GMT
Release Date Price: kr1.93
Per NorlÃ;n
Alligator Bioscience AB - CEO

© -

Thank you. Welcome to this webcast on our year-end report 2019. I will start by giving an overview of significant events during the last quarter and on our pipeline strategy.

So slide 2. And as usual, the presentation includes some forward-looking statements.

Let's move to slide 3. This is a summary of the key events of the year. As of October 28, Alligator regained full rights to mitazalimab, previously ADC-1013. We have conducted a thorough technology transfer from Janssen and now have full control of the data, the IP, and the clinical material.

As intensive planning undergoing to bring mitazalimab or mita into the next stage of clinical development, clinical Phase 2. We have plans to submit CTA for Phase 2 combination trial during the autumn. Partner discussions are ongoing, both for the purpose of co-development and for potential out-licensing. That said, in order to build the value and not to lose speed and time, we will bring mita into Phase 2 with or without a partner.

I'd also like to give a brief

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot